Alvotech is a global biopharmaceutical company specializing in the development and manufacturing of high-quality biosimilar products. It is part of the privately-owned international pharmaceutical group, Alvin Global Life Science. Alvotech was founded in 2013 and is headquartered in Reykjavik, Iceland. The company's mission is to provide patients worldwide with easier and more affordable access to high-quality, life-changing biopharmaceutical products.
Alvotech's robust pipeline primarily focuses on therapeutic areas such as autoimmunity, dermatology, oncology, ophthalmology, and inflammatory diseases. The company engages in robust, fully integrated in-house capabilities from cell line development to commercial manufacturing. This underscores the company's vertical integration, which is reflective of its commitment to those they provide.
The cornerstone of Alvotech is located in a state-of-the-art biopharmaceutical facility in Reykjavik, where products are developed and manufactured. Furthermore, Alvotech has a strong presence not only in Europe but also in Asia, North, and South America.
Alvotech’s visionary leader, Robert Wessman, has been instrumental in driving its fast-paced growth and establishing strategic partnerships to expand the company's global footprint. Driven by a team of international industry veterans, scientists, and biotech experts, the collective experience and knowledge have led to significant progress and milestones for Alvotech in a short span of time.
Alvotech's commitment to innovation is matched by its dedication to quality. The company operates strictly within the guidelines and regulations prescribed by international health authorities such as the EMA (European Medicines Agency), FDA (Food and Drug Administration), and PMDA (Pharmaceuticals and Medical Devices Agency) in Japan. These robust quality controls combine with their rigorous development process to ensure the safety and efficacy of all their products.
Alvotech prides itself on its steadfast commitment to improve patient accessibility to biological therapies. By providing high-quality, similar biological medicinal products at competitive prices, Alvotech has positioned itself as a key player in the global biosimilar market. Guided by a vision of transforming the lives of patients worldwide, Alvotech continues to drive change within the biopharmaceutical industry through innovation, quality, and a patient-centered approach.
This commitment to excellence and patient care has positioned Alvotech as an emerging leader in the biosimilars industry. With its integrated capabilities, expansive biosimilar pipeline, and global distribution network, Alvotech is well positioned to make a significant impact on global healthcare. Through its endeavour, Alvotech emphasises the importance of enabling access to advanced biological medication, confirming its place as a forward-thinking key player in the biopharmaceutical sector.